DICK'S Sporting Goods, Inc. (DKS)

CTI BioPharma Stock Forecast

Stock Price Forecast

The 19 analysts that cover CTI BioPharma stock have a consensus rating of "Buy" and an average price target of $230.79, which forecasts a 11.62% increase in the stock price over the next year. The lowest target is $185 and the highest is $294.

Price Target: $230.79 (+11.62%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$185	$230.79	$227	$294
Change	-10.53%	+11.62%	+9.78%	+42.19%

Analyst Ratings

The average analyst rating for CTI BioPharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	8	8	6	6	6	6
Buy	5	5	5	5	4	4
Hold	9	11	10	10	10	10
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	22	24	21	21	20	20

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Anthony Chukumba Loop Capital	Loop Capital	Hold Maintains $180 → $215	Hold	Maintains	$180 → $215	+3.98%	Jul 30, 2025
Michael Baker DA Davidson	DA Davidson	Strong Buy Maintains $230	Strong Buy	Maintains	$230	+11.23%	Jun 27, 2025
Robert Ohmes B of A Securities	B of A Securities	Strong Buy Maintains $250 → $240	Strong Buy	Maintains	$250 → $240	+16.07%	Jun 24, 2025
Michael Lasser UBS	UBS	Strong Buy Maintains $260 → $225	Strong Buy	Maintains	$260 → $225	+8.82%	May 29, 2025
Adrienne Yih Barclays	Barclays	Buy Maintains $217 → $232	Buy	Maintains	$217 → $232	+12.20%	May 29, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

14.09B

Increased by 4.79%

from 13.44B

Revenue Next Year

14.62B

Increased by 3.79%

from 14.09B

EPS This Year

14.47

Increased by 2.97%

from 14.05

EPS Next Year

15.47

Increased by 6.93%

from 14.47

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027	FY 2028
Period Ending	Jan 30, 2021	Jan 29, 2022	Jan 28, 2023	Feb 3, 2024	Feb 1, 2025	Feb 1, 2026	Feb 1, 2027	Feb 1, 2028
Revenue	9.58B	12.29B	12.37B	12.98B	13.44B	14.09B	14.62B	15.28B
Revenue Growth	9.52%	28.27%	0.61%	4.98%	3.53%	4.79%	3.79%	4.53%
EPS	5.72	13.87	10.78	12.18	14.05	14.47	15.47	16.44
EPS Growth	71.26%	142.49%	-22.28%	13.02%	15.34%	2.97%	6.93%	6.29%
Forward PE	-	-	-	-	-	14.29	13.36	12.57
No. Analysts	-	-	-	-	-	30	30	14

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028
High	15.1B	15.6B	16.4B
Avg	14.1B	14.6B	15.3B
Low	13.5B	13.8B	14.2B

Revenue Growth

Revenue Growth	2026	2027	2028
High	12.5%	11.0%	12.4%
Avg	4.8%	3.8%	4.5%
Low	0.5%	-1.8%	-2.7%

EPS Forecast

EPS	2026	2027	2028
High	15.46	17.08	18.90
Avg	14.47	15.47	16.44
Low	13.75	14.06	14.89

EPS Growth

EPS Growth	2026	2027	2028
High	10.0%	18.1%	22.2%
Avg	3.0%	6.9%	6.3%
Low	-2.2%	-2.8%	-3.8%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.